According to the Credit Suisse report, "Gleevec/Glivec is used much more frequently in the first line setting in the EU than the US (74% vs. 46%)." Using those percentages, until the EPIC results are in, Iclusig only has the possibility of being used in second-line 26% of the time in the EU (other than T315I).
Market Data 
Markets 
AI
